[{"from": "human", "value": "Provide a brief overview of this molecule. [C][O][C][=C][Branch1][=N][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][F][C][O][C][=C][Branch2][Ring2][Branch1][C][=C][Branch2][Ring1][#C][C][=Branch1][Ring2][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][Branch1][O][S][C][=C][Ring1][Branch1][N][C][Ring1][#Branch2][=O][C][=Branch1][C][=O][O][F][O][C]"}, {"from": "gpt", "value": "The molecule is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix].   Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with heavy menstrual bleeding, anemia, abdominal pain and pressure, bloating, increased urinary frequency, and reproductive dysfunction. As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial by preventing intramyometrial growths in the endometrial glands.  Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids."}]